Nicotinamide Riboside (NR): On Its Own or in a Synergistic Formula?

Nicotinamide riboside (NR) has gone from being a laboratory compound to one of the most studied supplements in the field of cellular vitality. As the market matures, one question becomes unavoidable among those who do their research before buying: does it make sense to take NR on its own, or are its benefits amplified when combined with other ingredients?

There is no single answer. The choice between a single-ingredient NR supplement and a synergistic formula depends on the user's profile, the wellness goal being pursued and, above all, on what current scientific evidence does —and does not— have to say about each combination.

This article analyses both approaches rigorously: what the science says about NR on its own, which combinations have clinical backing, which are theoretical, and how to make an informed decision.

What nicotinamide riboside is and why NAD+ matters

Nicotinamide riboside (NR) is a form of vitamin B3 and one of the most efficient precursors of NAD+ (nicotinamide adenine dinucleotide), a coenzyme present in every cell of the body. NAD+ is essential for cellular energy production, DNA repair and the regulation of proteins such as sirtuins —enzymes associated with the control of cellular ageing— and PARPs, involved in the response to genetic damage.

The problem is that NAD+ levels decline progressively with age. An analysis of human skin samples documented a significant negative correlation between age and NAD+ levels, with substantial decreases in older adults compared with younger ones. Neuroimaging studies using magnetic resonance have confirmed a similar pattern in brain tissue. Different methodologies, consistent conclusion: NAD+ falls over the years.

This is where NR comes in. Unlike other forms of vitamin B3 such as niacin or nicotinamide, NR is converted into NAD+ through a relatively direct metabolic route: NR → NMN (nicotinamide mononucleotide) → NAD+. Metabolic tracing studies suggest that part of the conversion may also occur via nicotinamide as an intermediate. This conversion efficiency is one of the reasons NR has accumulated more human clinical trials than any other NAD+ precursor.

The first clinical trial to show that oral NR supplementation raises blood NAD+ levels in humans was published by Trammell et al. in 2016 in the journal Nature Communications. Since then, more than a dozen controlled trials have replicated this finding at doses ranging from 250 mg to 1,000 mg per day.

The case for single-ingredient NR: what the clinical evidence says

Before assessing whether a synergistic formula adds extra value, it helps to understand what NR can do on its own. The available evidence is more solid than many consumers realise, but also more nuanced.

Increased blood NAD+: the most replicated finding

The best-established effect of NR is the rise in circulating NAD+. Controlled clinical trials in adults consistently show a statistically significant increase in blood NAD+ levels, with mean increases that, depending on dose and duration, sit roughly between 40% and 90% above baseline.

A randomized, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults (n = 24; Martens et al., 2018) showed that 1,000 mg/day of NR for 6 weeks raised NAD+ in peripheral blood mononuclear cells by around 60% relative to placebo.

NAD+ in muscle tissue: the effect reaches the target

That NR raises NAD+ in blood does not guarantee it does so in target tissues, so this question was addressed directly with muscle biopsy. Elhassan et al. (2019) supplemented 12 older men with 1 g/day of NR for 21 days in a crossover design: NR raised the NAD+ metabolome in muscle (measured by the increase in metabolites such as nicotinic acid dinucleotide and nicotinamide clearance products) and produced an anti-inflammatory transcriptomic signature.

In the same vein, a randomized, double-blind crossover trial in adults with overweight or obesity (Remie et al., 2020) confirmed that 1,000 mg/day of NR for 6 weeks raises NAD+ metabolites in muscle and, in addition, improves body composition: an increase in the percentage of lean mass (+1.34 points) with a reduction in fat mass, together with a rise in sleeping metabolic rate and a greater capacity to form acetylcarnitine (a marker of metabolic flexibility). These are modest but favourable changes, consistent with the effects observed on muscle tissue in these studies.

Physical performance: the first trial with a positive functional endpoint

The most relevant advance for the question "does this actually do something you can feel?" came with the NICE trial (McDermott et al., 2024), published in Nature Communications. It was a randomized, double-blind, placebo-controlled trial in 90 people with peripheral artery disease (a population with real walking disability) that assessed, as its primary endpoint, the distance covered in the 6-minute walk test. Unlike most previous studies, the endpoint here was not a biomarker but a clinical function that matters to the patient.

The results were positive. At 6 months, NR improved walking distance by +17.6 meters versus placebo, meeting the study's prespecified significance criterion. At 3 months the improvement was +22.4 meters, and among those who took at least 75% of the capsules the benefit rose to +31.0 meters, a magnitude the authors describe as comparable to that of supervised exercise in this disease. NR also increased the abundance of satellite cells in the gastrocnemius muscle, a marker of muscle regenerative capacity.

Brain NAD+, metabolism and clinical improvement

The NADPARK study (Brakedal et al., 2022), published in Cell Metabolism, took the question to the nervous system. In this randomized, double-blind, placebo-controlled trial, 30 patients with newly diagnosed, treatment-naïve Parkinson's disease received 1,000 mg/day of NR for 30 days. Using magnetic resonance spectroscopy, NR was shown to raise NAD+ levels in the brain, something few compounds manage to document non-invasively.

Beyond the biomarker, the patients in whom brain NAD+ increased showed altered cerebral metabolism (by PET) and a mild clinical improvement on the symptom scale (MDS-UPDRS), together with a reduction in inflammatory cytokines in blood and cerebrospinal fluid. The authors are cautious and theorise that NR may be a neuroprotective candidate that warrants larger trials, already under way. It is an open line of research, not a treatment.

Blood pressure and vascular function

The Martens group recorded, as a secondary finding, a reduction in systolic blood pressure in a subgroup of participants with elevated pressure, together with a trend towards lower arterial stiffness. The authors themselves urged caution, since this was an exploratory analysis in a small subgroup, but the finding is consistent with the mechanism (higher NAD+ favours nitric-oxide-mediated endothelial function) and with the improvement in walking capacity observed in the NICE trial. Vascular function is, today, one of the most active lines of NR research. This result describes an exploratory analysis and is not a property attributable to any product.

Inflammation and oxidative stress

Elhassan et al.'s 21-day study (2019) showed changes in the muscle transcriptomic profile with anti-inflammatory signatures and reductions in circulating markers such as IL-6 and TNF-α. This anti-inflammatory effect was replicated in a very different context: in NADPARK, NR reduced inflammatory cytokines in both blood and cerebrospinal fluid. The convergence of two different populations —ageing muscle and Parkinson's disease— strengthens the plausibility of a real anti-inflammatory effect, although in both cases these were secondary findings.

Limitations of the current evidence on NR alone

It would be dishonest not to mention the limitations. Many NR trials have moderate sample sizes (n < 100) and relatively short durations (from 4 weeks to 6 months). The most solid positive findings have been obtained in populations with a specific condition (peripheral artery disease), so their direct extrapolation to healthy people should be done with caution.

Even so, the balance is clearly favourable: the evidence supports that NR raises NAD+ safely and consistently in blood, muscle and brain, and is starting to accumulate positive results on real clinical outcomes (physical performance, symptomatic improvement, anti-inflammatory profile). Consolidating these benefits in larger and longer trials is the next frontier.

What a synergistic formula is and which combinations exist

A synergistic formula combines NR with one or more active ingredients in order to enhance, complement or broaden its effects on NAD+ metabolism or other pathways related to cellular vitality. The most frequent combinations in the market and the literature are the following.

NR + Resveratrol

Resveratrol is a polyphenol that directly activates sirtuins, the same proteins that NAD+ activates indirectly. The synergy hypothesis is that, while NR raises NAD+ levels —the "fuel" of sirtuins—, resveratrol acts as an "accelerator" of these enzymes. However, its oral bioavailability is low (around 1% of the ingested dose reaches systemic circulation) and human studies have produced more modest results than those obtained in animal models. This does not invalidate the synergy hypothesis with NR, but it does call for calibrated expectations.

NR + Pterostilbene

Pterostilbene is an analogue of resveratrol with greater oral bioavailability and the same sirtuin-activation mechanism. Dellinger et al. (2017) ran a double-blind trial with 120 adults that assessed the NR + pterostilbene combination (NRPT) against placebo, observing a dose-dependent rise in blood NAD+. The study did not include an NR-alone arm, so on its own it does not allow any conclusion about the superiority of the combination over NR alone. Some researchers consider pterostilbene a superior alternative to resveratrol for oral use, although the specific clinical evidence on its combination with NR remains limited.

NR + Quercetin

Quercetin is a flavonoid with senolytic properties: it may help eliminate senescent cells, those that have stopped dividing but remain metabolically active and secrete inflammatory factors. The combination with NR is based on the hypothesis that raising NAD+ enhances the autophagy and apoptosis mechanisms that quercetin activates. The direct clinical evidence for this combination is preliminary.

NR + TMG (trimethylglycine or betaine)

This is perhaps the combination with the strongest mechanistic backing. When NR raises NAD+, the synthesis and catabolism of NAD+ generate metabolites such as methylnicotinamide, which consume methyl groups from the cellular pool. If the availability of methyl groups were insufficient, the body might compensate by reducing other methylations, such as those of DNA. TMG acts as a methyl-group donor and, in theory, could offset this effect. The hypothesis has a plausible biochemical basis, but the direct clinical evidence in humans on the NR + TMG combination and its effect on DNA methylation patterns is still to be investigated.

NR + Coenzyme Q10

CoQ10 is an essential component of the electron transport chain. The synergy hypothesis rests on both acting on mitochondrial function through complementary routes: NR increases the NAD+ available to the dehydrogenases of the Krebs cycle, while CoQ10 optimises the efficiency of the respiratory chain. The clinical evidence for this specific combination is scarce, although each ingredient separately has solid clinical trials.

How to evaluate the evidence for a combined formula

Before deciding whether a synergistic formula is superior to single-ingredient NR, there is a fundamental methodological problem affecting almost all research on supplement combinations. It is worth understanding.

The attribution problem

When a study evaluates a formula containing NR + resveratrol + pterostilbene + CoQ10 and observes a positive effect, it is impossible to determine which ingredient —or which combination— produced it. This is called the attribution problem and is a critical limitation of most studies on combined formulas.

To establish real synergy, a trial needs at least four treatment arms: placebo, ingredient A alone, ingredient B alone, and A+B. Only then can it be determined whether the effect of the combination is additive (equal to the sum of the individual effects), synergistic (greater than the sum) or antagonistic (less than the sum). This factorial design is costly and uncommon in supplements. For reference, the most robust quantitative figure in the field —the ~60% rise in NAD+ with NR alone— comes from a study of NR as the sole active ingredient; the NRPT trials were compared against placebo, not against NR alone, so they do not allow any additional effect attributable to the combination to be quantified.

Three degrees of synergy the consumer should distinguish

• Demonstrated synergy: the effect of the combination has been directly compared with each component separately in a controlled human trial. In the NAD+ field, practically non-existent with a full factorial design.
• Plausible mechanistic synergy: the mechanisms of action are complementary and the hypothesis is supported in cellular or animal models. Example: NR + TMG (DNA methylation).
• Marketing synergy: the combination is presented as synergistic without verifiable mechanistic or clinical backing.

The golden rule

Before assuming a combined formula is superior to NR alone, ask: is there a controlled clinical trial that directly compares the formula with single-ingredient NR, at the same sample size and the same duration? If the answer is no —and it almost always is—, you are looking at a reasonable hypothesis, not at evidence of superiority.

When to choose single-ingredient NR

• To establish a baseline. If it is the first time supplementing with an NAD+ precursor, starting with NR alone makes it possible to assess the individual response without confounding variables.
• When taking other medications or supplements. Each additional ingredient introduces a potential for interaction. Single-ingredient NR has a well-documented safety profile in healthy adults and those with chronic conditions. Always consult your doctor or pharmacist before adding any supplement.
• When the dose matters. Trials have used specific doses (250, 500 and 1,000 mg/day). In a combined formula the NR dose may be diluted, ending up suboptimal.
• When transparency is a priority. "Proprietary blends" hide the exact dose of each ingredient. A single-ingredient product with a declared dose makes it possible to assess supplementation precisely.
• In people over 60 with no specific conditions. For the goal of maintaining the NAD+ levels associated with physiological ageing, the evidence with NR alone is solid enough; there is no evidence that a combined formula produces better results in this population at adequate doses.

When a synergistic formula may make sense

• When there is a well-defined secondary goal. If the aim is also to address another aspect (oxidative stress, low-grade inflammation, mitochondrial function), a formula with ingredients that have their own evidence in those areas may be coherent. The key: each ingredient must have independent evidence, not just the synergy hypothesis.
• When co-supplementation with TMG is justified. For those taking high doses of NR (≥ 500 mg/day) over a prolonged period, co-supplementation with TMG may be prudent to preserve the methyl-group pool. It is one of the few combinations with robust biochemical justification, although direct clinical evidence remains limited.
• In supervised cellular-vitality protocols. Some preventive and healthy-ageing medicine physicians design individualized protocols with biomarkers (blood NAD+, DNA methylation, inflammatory markers). In that monitored context, a combined formula may make sense.
• When adherence is decisive. If the real alternative is not "NR alone vs. NR + others" but "a combined capsule vs. taking nothing", the combined formula may be the more realistic option.

What a synergistic formula should NOT do

It should not include ingredients without their own evidence or a plausible mechanism in relation to NAD+. The presence of multiple ingredients at suboptimal doses —so-called "pixie dusting"— is a warning sign: the manufacturer may be adding ingredients to justify a premium price without any of them reaching the clinically supported dose.

Comparison table: single-ingredient NR vs. synergistic formula

There is no universal answer. The optimal decision depends on the individual profile, wellness goals, pharmacological situation and the level of evidence each person considers sufficient to act. What is universal is the need to read labels carefully, check the dose of each ingredient and consult a healthcare professional before starting any protocol.

Safety, side effects and contraindications

NR has a well-documented safety profile. Published trials, at doses of up to 1,000 mg/day for periods of up to 12 weeks, have not reported serious adverse effects. The most frequent side effects are mild and transient: nausea, gastrointestinal discomfort and, in some cases, skin flushing (flushing), although the latter is far less frequent with NR than with niacin.

The safety trial by Dellinger et al. (2017) with 120 adults found no differences in hepatic, renal or haematological parameters after 8 weeks of NRPT versus placebo. For NR as monotherapy, the studies by Dollerup et al. (2018), Remie et al. (2020), the NICE trial (McDermott et al., 2024, up to 6 months) and NADPARK (Brakedal et al., 2022) described good tolerability, with mild and transient adverse effects.

Groups who should consult their doctor before supplementing

• People with diagnosed liver or kidney disease.
• People being treated with drugs that affect NAD+ metabolism or DNA methylation.
• Pregnant or breastfeeding women (absence of safety data).
• People with a history of cancer, especially hormone-dependent tumours; consult the oncologist before starting any supplementation.
• People with disorders of vitamin B3 metabolism.

Additional considerations for combined formulas

Each additional ingredient introduces its own safety profile. Resveratrol may inhibit hepatic enzymes (CYP2C9) involved in the metabolism of anticoagulants such as warfarin, which could potentiate their effect; this interaction, described in case reports and pharmacological reviews, justifies caution in people on anticoagulation. Quercetin may interfere with the absorption of certain antibiotics. TMG may raise homocysteine in people with certain variants of folate metabolism.

Remember: before starting any supplementation protocol, consult your doctor or pharmacist. This information is educational in nature and does not replace individualized professional advice.

5 key takeaways

1. NR reliably raises NAD+. It is the NAD+ precursor with the most human clinical trials, and it consistently increases the levels of this coenzyme in blood, muscle and even brain.
2. The effect reaches the target and is starting to be felt. We are no longer talking only about biomarkers: the NICE trial showed a real improvement in walking capacity, and the NADPARK study documented elevated brain NAD+ with mild clinical improvement.
3. Good safety profile. At the doses studied (250 – 1,000 mg/day), NR is well tolerated; the side effects described are mild and transient.
4. Alone is often enough, and sometimes better. For maintaining the NAD+ associated with ageing, single-ingredient NR has the most solid evidence.
5. Combining makes sense when there is a reason. A synergistic formula is coherent if each ingredient has its own evidence or a robust mechanism (such as NR + TMG) and if the NR dose stays in the effective range.